On December 1, 2025, Autolus Therapeutics plc appointed Ryan Richardson as a Class I director effective immediately, who will serve until the 2028 annual meeting; he brings over 20 years of experience from BioNTech and investment banking, with a £33,000 annual retainer and an option grant of 80,000 shares at $1.41 each.